Effect of Ranolazine on A1C and Glucose Levels in Hyperglycemic Patients With Non-ST Elevation Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We determined the relationships between glycemia at randomization, concurrent antidiabetic therapy, and change in A1C and fasting plasma glucose (FPG) in patients with diabetes receiving standard treatment for diabetes and randomized to ranolazine or placebo within the MERLIN-TIMI-36 (MERLIN) study. Ranolazine is a novel first-in-class drug approved for treating angina pectoris. RESEARCH DESIGN AND METHODS: Randomization and 4-month glycemic and antidiabetes drug usage data from MERLIN were analyzed using Spotfire and SAS version 9.1 software. RESULTS: In patients with diabetes and A1C of ≥8–10% at randomization (n = 171), there was an absolute A1C reduction in the ranolazine group of 1.2% (95% CI −1.4 to −1.0), and the placebo-adjusted (n = 182) decrease in A1C by ranolazine was 0.59% (95% CI −0.99 to −0.20, P < 0.001). In patients with FPG of 150–400 mg/dl at randomization, ranolazine (n = 131) compared with placebo (n = 147) reduced FPG by 25.7 mg/dl (95% CI −43.3 to −8.1, P = 0.001). When changes in either A1C or FPG were correlated to A1C or FPG at randomization, the slopes were significantly steeper for ranolazine than placebo (A1C, P = 0.046; FPG, P < 0.001), indicating that lowering of A1C and FPG by ranolazine is related to hyperglycemia at randomization. Ranolazine, compared with placebo, was not associated with serious hypoglycemic events, associated with significant changes in concurrent antidiabetic therapy, or dependent on a history of angina. CONCLUSIONS: Ranolazine, when added to concurrent antidiabetes treatment, lowers FPG and A1C in patients with cardiovascular disease and poorly controlled diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both the antianginal effect259 and the glucose-lowering effect260–262 of ranolazine appear to be enhanced in patients with poorly controlled T2DM.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [262]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Authors/Task Force Members, Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,647
Norhammar, A., Tenerz, Å., Nilsson, G., Hamsten, A., Efendíc, S., Rydén, L., & Malmberg, K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09089-x · Cited by 1,112
Chaitman, B. R., Skettino, S. L., Parker, J. O., Hanley, P., Meluzin, J., Kuch, J., Pepine, C. J., Wang, W., Nelson, J. J., Hebert, D. A., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.045 · Cited by 567
Morrow, D. A. (2007) · JAMA · doi:10.1001/jama.297.16.1775 · Cited by 507
Self-citation
Research works printed but not linked: 1
- Dhalla, 2008, Ranolazine increases glucose stimulated insulin secretion in rats, J Am Coll Cardiol, 51, A321
Cited by
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina
Kosiborod, M., Arnold, S. V., Spertus, J. A., McGuire, D. K., Li, Y., Yue, P., Ben-Yehuda, O., Katz, A., Jones, P. G., Olmsted, A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.011 · Cited by 205
Self-citationRole of ranolazine in angina, heart failure, arrhythmias, and diabetes
Sossalla, S. T., & Maier, L. S. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.003 · Cited by 106
BUNCH, T. J., MAHAPATRA, S., MURDOCK, D., MOLDEN, J., WEISS, J. P., MAY, H. T., BAIR, T. L., MADER, K. M., CRANDALL, B. G., DAY, J. D., et al. (2011) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2011.03208.x · Cited by 101
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 94
Understanding hypoglycemia in hospitalized patients
Hulkower, R. D., Pollack, R. M., & Zonszein, J. (2014) · Diabetes Management · doi:10.2217/dmt.13.73 · Cited by 89
New and emerging drugs and targets for type 2 diabetes: reviewing the evidence.
Miller, B. R., Nguyen, H. T., Hu, C. J.-H., Lin, C., & Nguyen, Q. P. H. (2014) · PubMed · Cited by 86
Belsey, J., Savelieva, I., Mugelli, A., & Camm, A. J. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487314533217 · Cited by 83
Cassano, V., Leo, A., Tallarico, M., Nesci, V., Cimellaro, A., Fiorentino, T. V., Citraro, R., Hribal, M. L., Sarro, G. D., Perticone, F., et al. (2020) · Nutrients · doi:10.3390/nu12020382 · Cited by 69
Ning, Y., Wei, Z. C., Fu, Z., Jiang, J. Z., Liu, D., Belardinelli, L., & Dhalla, A. K. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176396 · Cited by 75
Self-citationAbnormal Myocardial Dietary Fatty Acid Metabolism and Diabetic Cardiomyopathy
Carpentier, A. C. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.029 · Cited by 71
Myocardial Metabolism in Diabetic Cardiomyopathy: Potential Therapeutic Targets
Sung, M. M. Y., Hamza, S. M., & Dyck, J. R. B. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6305 · Cited by 59
Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Eckel, R. H., Henry, R. R., Yue, P., Dhalla, A. K., Wong, P., Jochelson, P., Belardinelli, L., & Skyler, J. S. (2015) · Diabetes Care · doi:10.2337/dc14-2629 · Cited by 57
Self-citationBlockade of Na+ Channels in Pancreatic α-Cells Has Antidiabetic Effects
Dhalla, A. K., Yang, M., Ning, Y., Kahlig, K. M., Krause, M., Rajamani, S., & Belardinelli, L. (2014) · Diabetes · doi:10.2337/db13-1562 · Cited by 53
“P H A R M A C O L O G Y A N D T H E R A P E U T IC S Study (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes Study) demonstrated that ranolazine lowered HbA1c levels in patients with diabetes and reduced the incidence of newly elevated HbA1c levels in initially normog…”
InfluentialSelf-citationMedical treatment of stable angina: A tailored therapeutic approach
Manolis, A. J., Poulimenos, L. E., Ambrosio, G., Kallistratos, M. S., López-Sendón, J., Dechend, R., Mancia, G., & Camm, A. J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.150 · Cited by 54
Ranolazine recruits muscle microvasculature and enhances insulin action in rats
Fu, Z., Zhao, L., Chai, W., Dong, Z., Cao, W., & Liu, Z. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.257246 · Cited by 49
Management of stable angina: A commentary on the European Society of Cardiology guidelines
Ambrosio, G., Mugelli, A., Lopez-Sendon, J. L., Tamargo, J. L., & Camm, A. J. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316648475 · Cited by 45
Schwartz, S. S., & Kohl, B. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0468 · Cited by 40
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Majumdar, S. K., & Inzucchi, S. E. (2013) · Endocrine · doi:10.1007/s12020-013-9884-3 · Cited by 39
Trimetazidine and Other Metabolic Modifiers
Guarini, G., Huqi, A., Cardiovascular Medicine Division, O. D. V., Morrone, D., Capozza, P., & Marzilli, M. (2018) · European Cardiology Review · doi:10.15420/ecr.2018.15.2 · Cited by 31
Ren, L., Chen, X., Nie, B., Qu, H., Ju, J., & Bai, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.806966 · Cited by 28
Controversies in the cardiovascular management of type 2 diabetes
Opie, L. H., Yellon, D. M., & Gersh, B. J. (2010) · Heart · doi:10.1136/hrt.2010.214031 · Cited by 30
Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina
Banerjee, K., Ghosh, R. K., Kamatam, S., Banerjee, A., & Gupta, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.102 · Cited by 27
Elkholy, S. E., Elaidy, S. M., El-Sherbeeny, N. A., Toraih, E. A., & El-Gawly, H. W. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117557 · Cited by 27
Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus
Lamendola, P., Nerla, R., Pitocco, D., Villano, A., Scavone, G., Stazi, A., Russo, G., Franco, A. D., Sestito, A., Ghirlanda, G., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.10.051 · Cited by 24
Tamargo, J. L., & Lopez-Sendon, J. L. (2021) · Future Cardiology · doi:10.2217/fca-2021-0058 · Cited by 22
The Impact of Current and Novel anti-diabetic Therapies On Cardiovascular Risk
Ussher, J. R., Sutendra, G., & Jaswal, J. S. (2012) · Future Cardiology · doi:10.2217/fca.12.68 · Cited by 21
Diabetogenic effects of cardioprotective drugs
Bell, D. S. H., & Gonçalves, E. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14295 · Cited by 23
Mourouzis, I. S., Mantzouratou, P., Galanopoulos, G. T., Kostakou, E., Dhalla, A. K., Belardinelli, L., & Pantos, C. I. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414524481 · Cited by 23
Self-citationRanolazine: Multifaceted role beyond coronary artery disease, a recent perspective
Ghosh, G. C., Ghosh, R., Bandyopadhyay, D., Chatterjee, K., & Aneja, A. (2018) · Heart Views · doi:10.4103/heartviews.heartviews_18_18 · Cited by 22
Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris
Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-012-0005-z · Cited by 18
Pettus, J., McNabb, B., Eckel, R. H., Skyler, J. S., Dhalla, A. K., Guan, S., Jochelson, P., Belardinelli, L., & Henry, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12629 · Cited by 17
Self-citationStable angina pectoris: antianginal therapies and future directions
CHAITMAN, B. R., & Laddu, A. A. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.129 · Cited by 18
Selvarajan, S. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10594.5448 · Cited by 16
Caminiti, G., FOSSATI, C., Battaglia, D., Massaro, R., Rosano, G. M. C., & Volterrani, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.003 · Cited by 16
Nusca, A., Bernardini, F., Mangiacapra, F., Maddaloni, E., Melfi, R., Ricottini, E., Piccirillo, F., Manfrini, S., Ussia, G. P., & Grigioni, F. (2021) · Journal of Diabetes Research · doi:10.1155/2021/4952447 · Cited by 18
Ranolazine and Its Effects on Hemoglobin A 1C
Greiner, L., Hurren, K. M., & Brenner, M. J. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016631757 · Cited by 15
The Effect of Ranolazine on Glycemic Control: a Narrative Review to Define the Target Population
Lisi, D., Andrews, E., Parry, C., Hill, C., Ombengi, D., & Ling, H. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06917-6 · Cited by 14
Tawfik, M. K., & Ameen, A. M. (2019) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0571 · Cited by 15
Schwartz, S. S., & Herman, M. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1043182 · Cited by 14
Schwartz, S. S., Fabricatore, A. N., & Diamond, A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_31 · Cited by 17
Guarini, G., Huqi, A., Morrone, D., & Marzilli, M. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6677-y · Cited by 13
Efficacy and Safety of Ranolazine in Diabetic Patients: A Systematic Review and Meta-analysis
Zeng, X., Zhang, Y., Lin, J.-H., Zheng, H., Peng, J., & Huang, W. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017747901 · Cited by 15
Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus
Gilbert, B. W., Sherard, M. K., Little, L., Branstetter, J. W., Meister, A., & Huffman, J. B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.11.021 · Cited by 13
Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes
Schwartz, S. J. (2013) · Drugs in Context · doi:10.7573/dic.212255 · Cited by 15
Page, R. L., II, Ghushchyan, V. H., Read, R. A., Hartsfield, C. L., Koch, B., & Nair, K. V. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.08.002 · Cited by 11
Khazraei, H., Mirkhani, H., & Purkhosrow, A. (2013) · Acta Physiologica Hungarica · doi:10.1556/aphysiol.100.2013.2.3 · Cited by 10
Ambrosio, G., Tamargo, J. L., & Grant, P. J. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115609028 · Cited by 11
Teoh, I. H., & Banerjee, M. (2018) · Open Heart · doi:10.1136/openhrt-2017-000706 · Cited by 9
Esenboğa, K., Kurtul, A., Nazman, H., Tekin, C. G., Özyüncü, N., Tan, T. S., Tutar, E., & Turhan, S. (2021) · Angiology · doi:10.1177/00033197211005590 · Cited by 10
Clinical Update on Nursing Home Medicine: 2011
Messinger‐Rapport, B. J., Morley, J. E., Thomas, D. R., & Gammack, J. K. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.08.007 · Cited by 7
Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia
Dvir, D., & Battler, A. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6254-8 · Cited by 8
Friedewald, V. E., Hayes, S. N., Pepine, C. J., Roberts, W. C., & WENGER, N. K. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.09.003 · Cited by 6
The Impact of Cardiovascular Drugs on Glycemic Control: A Review
Grodzinsky, A., Arnold, S. V., Jacob, D., Draznin, B., & Kosiborod, M. (2016) · Endocrine Practice · doi:10.4158/ep161309.ra · Cited by 8
Use of Ranolazine in Patients with Stable Angina Pectoris
Khera, S., Kolte, D. S., & Aronow, W. S. (2014) · Cardiology · doi:10.1159/000358871 · Cited by 6
Contemporary Antianginal Therapy
Patel, S. Y., Patel, V. H., Ayyad, M., Palani, A., & Allencherril, J. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00766-5 · Cited by 6
Non-coding RNAs modulate pyroptosis in diabetic cardiomyopathy: A comprehensive review
Shang, W., Geng, X., Sun, X., Fan, X., Li, A., Zhang, C., Kang, Y., Liang, Y., & Zhang, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142865 · Cited by 5
Indicaciones actuales de tratamiento médico
Arós, F., Rekondo, J., Morillas, M., & Lekuona, I. (2012) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(12)70068-7 · Cited by 4
Elkholy, S. (2020) · Medicine Updates · doi:10.21608/muj.2020.25106.1007 · Cited by 4
On The Horizon: New Oral Therapies for Type 2 Diabetes Mellitus
Ukrainski, M., Gandrabura, T., Ln, B., & Ahmed, I. (2013) · International Journal of Diabetology & Vascular Disease Research · doi:10.19070/2328-353x-130004 · Cited by 3
Nitrates and newer antianginals
Opie, L. H., & Horowitz, J. D. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-3322-4.00011-9 · Cited by 5
Singh, D., Oladimeji-Salami, J. A., & Akindele, A. J. (2025) · Experimental Biology and Medicine · doi:10.3389/ebm.2025.10604 · Cited by 2
Elsawy, S., Nabiel, A. M., Mohamed, M. M., & Hassan, R. E. (2020) · Medicine Updates · doi:10.21608/muj.2020.23326.1002 · Cited by 4
The Effects of Ranolazine on Hemoglobin A1c in a Veteran Population.
Greiner, L., Hurren, K. M., & Brenner, M. J. (2018) · Europe PMC (PubMed Central) · Cited by 2
Budania, N., Kumar, A., Sharma, P., Saharan, S., & Kumar, A. H. S. (2013) · International Journal of Biomedical and Advance Research · doi:10.7439/ijbar.v4i10.508 · Cited by 1
Inhibition of Fatty Acid Oxidation to Treat Heart Failure in Patients
Yan, R., Wei, J. J., & Gao, D. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1227-8_16 · Cited by 1
Select medications that unexpectedly lower HbA1c levels
Tillman, F., & Kim, J. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12689 · Cited by 1
Verrier, R. L. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.260687
Pathophysiology of the late sodium current: from myocardium to pancreatic beta cells
Rizzetto, R. (2013) · BOA (University of Milano-Bicocca)
Antidiabetic drugs of interest
Kvapil, M. (2016) · Interní medicína pro praxi · doi:10.36290/int.2016.036
Effect of ranolazine on HbA1c and blood glucose levels in diabetic patients with chronic angina
Shilpa, B. N., Shashikala, G. H., Siddesh, & Mallesh, P. (2019) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20190647
Ranolazine in Stable Angina: Mechanism of Action and Therapeutic Implications
Zaza, A. (2013) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm13s1s0004
Pratiti, R., Sud, P., Yousef, M., & Moza, A. (2022) · Frontiers in cardiovascular drug discovery · doi:10.2174/9789815036909122060003
Current literature in diabetes
(2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1029
Case 52: Refractory Angina in a Patient with Type 2 Diabetes
Kosiborod, M. (2015) · American Diabetes Association eBooks · doi:10.2337/9781580405713.52
Efficacy of Ranolazine in Lowering HbA1c in Patients with Type 2 Diabetes Mellitus: A Meta-analysis
Ramos, E. F., Uy, A. B., & Loyola, A. B. (2017) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.178e62ed8e
Kumari, N., Arya, A. K., Prakash, V., Hameed, S., Mishra, H., & Dikshit, H. (2026) · Cureus · doi:10.7759/cureus.101227
MODERN OPTIMAL DRUG THERAPY OF STABLE ANGINA
Skybchyk, V., Turba, O., & Kysil, O. Y. (2025) · Acta Medica Leopoliensia · doi:10.25040/aml2025.3-4.110
Metadata
- Authors
- Chisholm, J. W., Goldfine, A. B., Dhalla, A. K., Braunwald, E., Morrow, D. A., Karwatowska-Prokopczuk, E., & Belardinelli, L.
- Affiliations
- Gilead Sciences (United States) (US)
- Joslin Diabetes Center (US)
- TIMI Study Group, Brigham and Women's Hospital and Department of Medicine, Boston, Massachusetts;
- Brigham and Women's Hospital (US)
- Division of Cardiovascular Therapeutics, Gilead Sciences, Palo Alto, California;
- Corresponding author
- Chisholm, Jeffrey W.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-03-31
- Volume
- 33
- Issue
- 6
- Pages
- 1163-1168
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2875416
- OpenAlex
- W2130710856
- Cited by
- 78
- References
- 25
- Citations by year
- 2026: 1 · 2025: 4 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 6 · 2017: 2 · 2016: 9 · 2015: 7 · 2014: 9 · 2013: 13 · 2012: 4
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Gilead Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- ranolazine, glycemic control, HbA1c, fasting blood glucose, hyperglycemia, non-ST-elevation acute coronary syndrome, diabetes mellitus, antidiabetic therapy, hypoglycemia, angina pectoris, cardiovascular disease
- MeSH terms
- Ranolazine, Acetanilides, Aged, Blood Glucose, Enzyme Inhibitors, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, Piperazines, Placebo Effect, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.